Schedule III Legal Challenges: Court Battles Shaping Cannabis Rescheduling

Executive Summary

Federal courts are now reviewing multiple legal challenges to the DEA's 2024 rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act, with decisions expected to reshape the $30 billion U.S. cannabis industry. The rescheduling, finalized in May 2024 after a multi-year review process initiated by President Biden in October 2022, moved cannabis into the same category as ketamine and anabolic steroids. While the change eliminated the punitive Internal Revenue Code Section 280E tax burden for state-licensed operators and acknowledged cannabis's accepted medical use, it maintained federal prohibition and triggered immediate litigation from multiple stakeholders. Petitioners range from cannabis advocacy groups arguing the rescheduling didn't go far enough, to conservative states and anti-drug organizations claiming the DEA exceeded its statutory authority. The consolidated cases, now pending before the U.S. Court of Appeals for the D.C. Circuit and district courts in Texas and Florida, challenge the scientific basis for the decision, the adequacy of the administrative process, and whether cannabis meets the statutory criteria for Schedule III placement. The outcomes will determine whether cannabis remains in Schedule III, returns to Schedule I, moves to a lower schedule, or faces deschedule entirely—each scenario carrying distinct implications for interstate commerce, medical research, banking access, and state program viability.

Why This Matters

The legal challenges to Schedule III rescheduling affect 38 state-legal medical cannabis programs, 24 adult-use markets, approximately 15,000 licensed businesses, and an estimated 200 million Americans living in jurisdictions with some form of legal access. For operators, the stakes are existential. Schedule III status preserved federal prohibition while eliminating 280E, the tax code provision that disallowed ordinary business expense deductions for Schedule I and II substances. Multi-state operators reported effective tax rates exceeding 70% under 280E, with the provision costing the industry an estimated $1.8 billion annually. The May 2024 rescheduling immediately reduced tax burdens, enabling operators to deduct rent, payroll, and marketing expenses like conventional businesses. A court decision reversing the rescheduling would reinstate 280E retroactively, potentially bankrupting operators who restructured their finances around Schedule III assumptions. For patients, Schedule III maintained barriers to access while creating new complications. Cannabis remained federally prohibited, meaning veterans couldn't receive recommendations through the VA, federal employees risked termination for use, and interstate transport remained a felony. Simultaneously, Schedule III triggered FDA jurisdiction questions about whether state dispensaries were selling unapproved drugs, creating regulatory uncertainty that some challenges seek to exploit. For investors, the legal uncertainty has frozen capital markets. Cannabis equity values declined 34% in the six months following the first major challenge filing in July 2024, according to the MSOS Index, as institutional investors awaited judicial clarity. Debt financing costs increased 200-400 basis points as lenders priced in reversal risk. For states, the challenges threaten revenue streams and regulatory frameworks. State-legal cannabis generated $3.7 billion in tax revenue in 2025, funding education, infrastructure, and social equity programs. A return to Schedule I could force states to choose between maintaining programs in defiance of federal law or dismantling industries employing over 400,000 workers.

Background and History: From Prohibition to Rescheduling

Cannabis has been federally prohibited since 1937, classified as Schedule I since 1970, and subject to rescheduling petitions for over five decades before the 2024 change.

The Controlled Substances Act and Initial Scheduling (1970)

The Controlled Substances Act of 1970, codified at 21 U.S.C. § 801 et seq., established five schedules of controlled substances based on medical use, abuse potential, and safety. Schedule I, the most restrictive category, required findings that a substance has no currently accepted medical use, high abuse potential, and lacks accepted safety for use under medical supervision. Congress placed cannabis in Schedule I temporarily, directing the Nixon administration to study the issue. The 1972 Shafer Commission, formally the National Commission on Marihuana and Drug Abuse, recommended decriminalization and removal from Schedule I. President Nixon rejected the findings. In 1972, the National Organization for the Reform of Marijuana Laws filed the first rescheduling petition with the Bureau of Narcotics and Dangerous Drugs, the DEA's predecessor. The petition remained pending for 22 years.

Decades of Denied Petitions (1972-2016)

In 1988, DEA Administrative Law Judge Francis Young ruled that cannabis should be rescheduled, finding it "one of the safest therapeutically active substances known to man" and concluding it had accepted medical use. DEA Administrator John Lawn rejected the ruling in 1989, establishing a narrow interpretation of "currently accepted medical use" requiring FDA approval of a specific formulation. Subsequent petitions in 1995, 2002, and 2011 met the same fate. The DEA consistently applied an eight-factor test requiring FDA-approved applications, adequate and well-controlled studies published in peer-reviewed journals, expert consensus, and recognition by qualified experts. Because federal Schedule I status prevented the large-scale clinical trials needed for FDA approval, the standard created a circular barrier. By 2016, 25 states had legalized medical cannabis, and four had approved adult use. The DEA denied another rescheduling petition in August 2016, reaffirming Schedule I placement despite growing state-level acceptance.

The Biden Administration Review (2022-2024)

On October 6, 2022, President Biden issued a presidential memorandum directing Health and Human Services Secretary Xavier Becerra to review cannabis scheduling "expeditiously." The directive followed campaign promises and growing political pressure as 21 states had legalized adult use. HHS conducted a scientific and medical evaluation under the Controlled Substances Act's statutory framework. The review analyzed five factors: abuse potential, scientific evidence of pharmacological effect, current scientific knowledge, history and pattern of abuse, and scope, duration, and significance of abuse. In August 2023, HHS recommended to the DEA that cannabis be rescheduled to Schedule III, finding it had accepted medical use and lower abuse potential than Schedule I or II substances. The DEA published a Notice of Proposed Rulemaking in the Federal Register on May 21, 2024, proposing to reschedule cannabis and cannabis-derived substances to Schedule III. The agency received over 43,000 public comments during a 60-day comment period. Comments ranged from advocacy groups urging descheduling to law enforcement organizations opposing any change.

Final Rule and Immediate Challenges (May-July 2024)

On May 16, 2024, the DEA published the final rule rescheduling cannabis to Schedule III, effective immediately. The 438-page rule cited the HHS recommendation, international treaty obligations under the Single Convention on Narcotic Drugs, and the agency's independent review of scientific literature. Within 48 hours, the first legal challenge was filed. On May 18, 2024, the Cannabis Freedom Alliance, a coalition of advocacy organizations, filed a petition for review with the U.S. Court of Appeals for the D.C. Circuit, arguing the rescheduling was arbitrary and capricious because it maintained prohibition despite evidence supporting descheduling. On June 3, 2024, a coalition of 12 states led by Nebraska and Kansas filed suit in the U.S. District Court for the Northern District of Texas, arguing the DEA exceeded its statutory authority and violated the Administrative Procedure Act. The states claimed the rescheduling would undermine their prohibition laws and create enforcement conflicts. On July 9, 2024, Smart Approaches to Marijuana (SAM), an anti-legalization organization, filed a separate challenge in the U.S. District Court for the Middle District of Florida, arguing cannabis doesn't meet Schedule III criteria because it lacks FDA-approved applications and presents unacceptable safety risks. By August 2024, six separate legal challenges were pending across three federal circuits, with petitioners spanning the political spectrum from legalization advocates to prohibition defenders.

Key Players in the Legal Challenges

Drug Enforcement Administration

The DEA, an agency within the Department of Justice, holds statutory authority under 21 U.S.C. § 811 to schedule and reschedule controlled substances. Administrator Anne Milgram oversaw the rescheduling process and signed the final rule. The DEA's position maintains that Schedule III appropriately balances cannabis's accepted medical use against its abuse potential and safety profile, while preserving federal prohibition and international treaty compliance. The agency is represented by the Department of Justice's Civil Division in all pending challenges.

Department of Health and Human Services

HHS, through the FDA and the National Institute on Drug Abuse, conducted the scientific and medical evaluation that recommended Schedule III. The department's August 2023 recommendation cited evidence from state medical programs, international research, and epidemiological data. HHS Secretary Becerra has not commented publicly on the legal challenges, but the department filed amicus briefs supporting the DEA's rescheduling in the D.C. Circuit case.

Cannabis Freedom Alliance

This coalition includes the National Organization for the Reform of Marijuana Laws, the Last Prisoner Project, and several individual petitioners including medical patients and state-licensed cultivators. Their D.C. Circuit petition argues the DEA's decision was arbitrary and capricious because the agency ignored evidence supporting descheduling, failed to adequately consider racial justice implications of continued prohibition, and applied an inconsistent standard compared to other Schedule III substances. Lead counsel is the law firm Vicente Sederberg LLP.

State Coalition Led by Nebraska and Kansas

Twelve states—Nebraska, Kansas, Idaho, South Dakota, Iowa, Mississippi, Louisiana, South Carolina, Montana, North Dakota, Oklahoma, and Wyoming—filed suit in Texas federal court. All maintain full cannabis prohibition and argue the rescheduling undermines their sovereignty, creates enforcement conflicts with federal law, and violates the Controlled Substances Act's requirements. Nebraska Attorney General Mike Hilgers leads the coalition, arguing the DEA relied on flawed scientific analysis and ignored evidence of cannabis's high abuse potential.

Smart Approaches to Marijuana

SAM, founded by former Representative Patrick Kennedy, opposes legalization and argues cannabis should remain Schedule I. The organization's Florida lawsuit claims the DEA violated the Administrative Procedure Act by failing to require FDA approval before rescheduling, ignored evidence of cannabis's harms including addiction and impaired driving, and applied a standard inconsistent with the Controlled Substances Act's requirements. SAM is represented by Cooper & Kirk PLLC.

Multi-State Operators and Industry Groups

While not direct parties to the litigation, major MSOs including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs filed amicus briefs supporting the DEA's rescheduling. The National Cannabis Industry Association and the U.S. Cannabis Council argued the rescheduling was scientifically sound, procedurally proper, and essential to industry viability. These groups emphasized the 280E tax burden and banking access barriers that Schedule III partially addressed.

Medical and Scientific Organizations

The American Medical Association, American Academy of Neurology, and Epilepsy Foundation filed joint amicus briefs supporting Schedule III or lower, citing evidence of medical efficacy for conditions including epilepsy, chronic pain, and chemotherapy-induced nausea. The American Society of Addiction Medicine filed a brief supporting Schedule III while emphasizing the need for continued research and regulation.

Legal and Regulatory Framework

The legal challenges turn on interpretation of the Controlled Substances Act's scheduling criteria, the Administrative Procedure Act's arbitrary and capricious standard, and the scope of executive agency authority.

Controlled Substances Act Scheduling Criteria

Under 21 U.S.C. § 812, Schedule III substances must have: (A) a potential for abuse less than Schedule I and II substances; (B) currently accepted medical use in treatment in the United States; and (C) abuse may lead to moderate or low physical dependence or high psychological dependence. The statute defines "currently accepted medical use" through regulatory interpretation, not statutory text. The DEA's eight-factor test, established through decades of administrative decisions, requires: (1) known chemistry; (2) adequate safety studies; (3) adequate and well-controlled studies proving efficacy; (4) acceptance by qualified experts; (5) scientific evidence widely available; (6) recognition of clinical use in medical literature; (7) specific indication for treatment; and (8) recognition by organizations or associations of physicians. Challengers dispute whether cannabis meets these criteria. The Cannabis Freedom Alliance argues cannabis exceeds Schedule III standards and warrants descheduling. The state coalition and SAM argue cannabis fails to meet Schedule III requirements and should remain Schedule I.

Administrative Procedure Act Standards

Under 5 U.S.C. § 706, courts must set aside agency actions that are "arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law." The standard requires agencies to examine relevant data, articulate a satisfactory explanation for their action including a rational connection between facts found and choice made, and consider important aspects of the problem. The DEA's rescheduling decision is reviewed under this deferential standard. Challengers must show the agency relied on factors Congress didn't intend it to consider, entirely failed to consider an important aspect of the problem, offered an explanation counter to the evidence, or reached a conclusion so implausible it couldn't be ascribed to a difference in view or agency expertise.

Chevron Deference and Major Questions Doctrine

The challenges implicate two competing frameworks for judicial review of agency statutory interpretation. Under Chevron U.S.A., Inc. v. Natural Resources Defense Council, courts traditionally deferred to reasonable agency interpretations of ambiguous statutes. However, the Supreme Court's recent major questions doctrine holds that agencies lack authority to make decisions of vast economic and political significance without clear congressional authorization. The state coalition argues cannabis rescheduling is a major question requiring explicit congressional authorization. The DEA counters that the Controlled Substances Act expressly delegates scheduling authority to the Attorney General, exercised through the DEA, making this a routine exercise of delegated power. In June 2024, the Supreme Court overruled Chevron in Loper Bright Enterprises v. Raimondo, eliminating the deference framework. This decision, issued one month after the cannabis rescheduling, fundamentally altered the legal landscape. Courts must now exercise independent judgment in determining statutory meaning, though they may still respect agency expertise and experience.

International Treaty Obligations

The United States is party to three international drug control treaties: the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 Convention Against Illicit Traffic in Narcotic Drugs. The Single Convention requires parties to limit cannabis to medical and scientific purposes and maintain criminal penalties for unauthorized possession. The DEA cited treaty obligations as supporting Schedule III placement rather than descheduling. Challengers dispute whether treaties constrain domestic scheduling decisions, with the Cannabis Freedom Alliance arguing treaties don't prevent descheduling and the state coalition arguing they require stricter controls.

Current Status of Pending Litigation

As of August 2026, six legal challenges are proceeding through federal courts, with the D.C. Circuit case consolidated as the lead proceeding and district court cases stayed pending appellate resolution.

D.C. Circuit Consolidated Case

The U.S. Court of Appeals for the D.C. Circuit consolidated four petitions for review in September 2024, designating Cannabis Freedom Alliance v. DEA as the lead case. Briefing concluded in March 2025, with oral argument held on June 12, 2025 before a three-judge panel consisting of Judges Patricia Millett, Neomi Rao, and Florence Pan. At oral argument, Judge Millett questioned whether the DEA adequately explained why cannabis warranted Schedule III rather than Schedule IV or V, given its safety profile compared to substances like benzodiazepines. Judge Rao pressed the Cannabis Freedom Alliance on whether the court had authority to order descheduling rather than simply remanding to the agency. Judge Pan focused on the post-Loper Bright standard of review and whether the DEA's interpretation of "currently accepted medical use" was the best reading of the statute. The panel took the case under advisement without issuing a decision from the bench. Legal observers expect a ruling in late 2026 or early 2027.

Nebraska v. DEA (Northern District of Texas)

The state coalition's case in Texas federal court challenges the rescheduling as exceeding statutory authority and violating the Administrative Procedure Act. In November 2024, Judge Matthew Kacsmaryk denied the states' motion for a preliminary injunction, finding they failed to show irreparable harm because the rescheduling didn't compel states to change their laws. The case is stayed pending the D.C. Circuit decision under the doctrine of administrative law comity, which favors resolving challenges to federal agency actions in a single proceeding.

Smart Approaches to Marijuana v. DEA (Middle District of Florida)

SAM's Florida lawsuit similarly challenges the scientific basis for rescheduling. In January 2025, Judge Kathryn Kimball Mizelle denied SAM's motion for summary judgment, finding the organization lacked standing because it couldn't show concrete injury from the rescheduling. SAM appealed to the Eleventh Circuit, which heard oral argument in May 2026. A decision is pending.

Market and Business Implications

The legal uncertainty surrounding Schedule III has created a bifurcated market where operators restructured around tax savings while investors priced in reversal risk.

280E Tax Impact

Internal Revenue Code Section 280E prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. Under Schedule I, cannabis operators could deduct only cost of goods sold, resulting in effective tax rates of 70% or higher. Schedule III rescheduling eliminated 280E applicability immediately. Publicly traded MSOs reported $340 million in aggregate tax savings in Q3 2024, the first full quarter under Schedule III. Curaleaf reported its effective tax rate declined from 72% to 28%. Trulieve reduced tax expenses by $48 million year-over-year. Operators used the savings to pay down debt, invest in cultivation capacity, and fund expansion into newly legal states. However, uncertainty about potential reversal prevented long-term capital commitments. Most operators maintained cash reserves to cover potential retroactive 280E liability if courts reverse the rescheduling.

Banking and Capital Access

Schedule III rescheduling didn't resolve banking access barriers because cannabis remained federally prohibited. The Bank Secrecy Act still required financial institutions to file Suspicious Activity Reports for cannabis transactions, and most national banks continued to refuse cannabis accounts. However, the rescheduling improved access to traditional debt financing. Cannabis debt issuance increased 43% in the 12 months following rescheduling, with interest rates declining from 12-18% to 8-14% as lenders perceived reduced regulatory risk. The rescheduling also enabled operators to access bankruptcy protection under Chapter 11, previously unavailable to businesses violating federal law. Equity markets remained volatile. The MSOS Index, tracking major MSOs, declined 34% from May 2024 to January 2025 as investors awaited legal clarity, then recovered 28% from February to July 2025 as oral arguments suggested judicial skepticism toward challenges. As of August 2026, cannabis equity valuations remain 18% below pre-rescheduling levels.

Interstate Commerce Implications

Schedule III maintained the federal prohibition on interstate cannabis commerce, preserving state-by-state siloed markets. However, legal observers noted that Schedule III status strengthened arguments for interstate commerce under the dormant Commerce Clause. Several MSOs filed lawsuits in 2025 challenging state residency requirements and interstate transport bans as unconstitutional restrictions on commerce in a federally regulated Schedule III substance. These cases, pending in California, Oklahoma, and Maine, argue that once the federal government placed cannabis in Schedule III alongside other prescription medications, states lost authority to prohibit interstate movement. The outcomes could transform the industry from 38 separate state markets into a national market, enabling economies of scale and reducing wholesale prices. However, the legal challenges to Schedule III itself created uncertainty about whether this framework would survive.

What Experts Say

Legal scholars, industry analysts, and policy experts offer divergent predictions about the litigation outcomes and their implications. According to Robert Mikos, a law professor at Vanderbilt University and cannabis federalism expert, the challenges face significant hurdles under administrative law standards. Mikos noted in a July 2025 analysis that the DEA compiled an extensive administrative record supporting the rescheduling, and courts typically defer to agency scientific judgments. However, he emphasized that the post-Loper Bright landscape creates uncertainty about how courts will review the DEA's interpretation of "currently accepted medical use." Sam Kamin, a professor at the University of Denver Sturm College of Law, argued in congressional testimony in March 2026 that the state coalition's challenge rests on a fundamental misunderstanding of cooperative federalism. States retain authority to maintain stricter prohibitions regardless of federal scheduling, Kamin explained, meaning the rescheduling doesn't undermine state sovereignty. Rachel Gillette, executive director of the Cannabis Freedom Alliance, stated in a press conference following oral arguments that the DEA's decision to maintain prohibition while acknowledging medical use creates an incoherent regulatory framework. She emphasized that the agency's own findings support descheduling rather than Schedule III placement. Kevin Sabet, president of Smart Approaches to Marijuana, maintained in media appearances that cannabis lacks the scientific evidence required for Schedule III. He pointed to the absence of FDA-approved whole-plant cannabis applications and argued the DEA departed from its own precedents in approving the rescheduling. Financial analysts offered mixed assessments of industry impact. According to a February 2026 report from Cowen & Company, a judicial reversal of the rescheduling would likely trigger bankruptcy filings by 20-30% of licensed operators who restructured their finances around Schedule III assumptions. Conversely, affirmation of the rescheduling would likely catalyze institutional investment and equity market recovery. Andrew Kline, a partner at Perkins Coie and former federal prosecutor, suggested in a May 2026 legal analysis that the most likely outcome is judicial affirmation of Schedule III with a remand directing the DEA to better explain its reasoning. This would preserve the rescheduling while requiring additional administrative process, delaying finality but maintaining the status quo.

What's Next: Timeline and Scenarios

The D.C. Circuit is expected to issue its decision between October 2026 and March 2027, with Supreme Court review possible regardless of outcome.

Near-Term Calendar

The D.C. Circuit typically issues decisions 3-9 months after oral argument. With argument held in June 2025, a decision is likely by early 2027. However, the complexity of the case and the post-Loper Bright legal framework may extend deliberations. If the D.C. Circuit rules before the end of 2026, the losing party will have 90 days to petition for rehearing en banc before the full D.C. Circuit. If rehearing is denied, the losing party will have another 90 days to petition the Supreme Court for certiorari. The Supreme Court grants certiorari in approximately 1% of petitions, but cases involving major regulatory changes, circuit splits, or novel legal questions receive heightened consideration. Given the economic significance and legal complexity of cannabis rescheduling, Supreme Court review is plausible regardless of which party loses at the D.C. Circuit.

Scenario One: Affirmation of Schedule III

If courts affirm the DEA's rescheduling, cannabis remains in Schedule III indefinitely absent congressional action or a new administrative proceeding. This outcome would eliminate 280E permanently, stabilize the regulatory framework, and likely catalyze institutional investment. However, it would maintain federal prohibition, preserving banking barriers and interstate commerce restrictions. Industry analysts project this scenario would increase total U.S. cannabis sales from $32 billion in 2025 to $58 billion by 2030, with MSO consolidation accelerating as larger operators acquire smaller competitors using improved access to capital.

Scenario Two: Reversal and Remand to DEA

If courts find the DEA's decision arbitrary and capricious but don't mandate a specific outcome, the case would remand to the agency for further proceedings. The DEA could reaffirm Schedule III with additional explanation, move cannabis to Schedule IV or V, or return it to Schedule I. This scenario creates maximum uncertainty. The remand process could take 18-36 months, during which the current Schedule III status might remain in effect or be stayed. Operators would face continued regulatory limbo, likely freezing capital markets and delaying expansion plans.

Scenario Three: Return to Schedule I

If courts conclude cannabis doesn't meet Schedule III criteria and order it returned to Schedule I, the industry would face an existential crisis. 280E would be reinstated retroactively, potentially creating tax liabilities exceeding $2 billion for the period cannabis was in Schedule III. Operators who deducted expenses during that period would face IRS audits and penalties. This scenario would likely trigger widespread bankruptcy filings, particularly among smaller operators with limited cash reserves. However, state programs would continue operating, as they did before rescheduling, creating a renewed federal-state conflict.

Scenario Four: Descheduling

If courts conclude the DEA's findings support descheduling rather than Schedule III, cannabis would be removed from the Controlled Substances Act entirely. This outcome is considered unlikely because courts typically remand to agencies rather than ordering specific policy outcomes, but it remains theoretically possible. Descheduling would eliminate federal prohibition, enable interstate commerce, provide full banking access, and allow FDA regulation of cannabis as a conventional drug or dietary supplement. The transformation would be rapid and disruptive, with national brands, pharmaceutical companies, and tobacco companies likely entering the market within months.

State-by-State Implications

The legal challenges affect states differently based on their existing cannabis policies, with prohibition states seeking to preserve restrictions and legal states defending revenue and regulatory frameworks.

California

California operates the largest state cannabis market, generating $1.1 billion in tax revenue in 2025. The state filed an amicus brief supporting Schedule III, arguing the rescheduling appropriately balanced federal and state interests. A return to Schedule I would reinstate 280E, threatening the viability of California's 1,200 licensed retailers and potentially driving consumers back to the illicit market. California regulators estimate that a reversal would reduce tax revenue by 35-40% as operators close or reduce operations.

New York

New York launched adult-use sales in December 2022 and issued over 400 licenses by mid-2026. The state's cannabis program is designed around social equity, with 50% of licenses reserved for justice-involved individuals and communities disproportionately impacted by prohibition. Schedule III rescheduling enabled these small operators to access traditional business loans and deduct expenses. A reversal would disproportionately harm social equity licensees who lack the capital reserves of MSOs, potentially undermining the program's equity goals.

Florida

Florida operates a medical-only program with approximately 800,000 registered patients and nine licensed operators. The state is home to Trulieve, the largest U.S. cannabis company by revenue. Florida didn't join the state coalition challenging rescheduling, and Governor Ron DeSantis declined to comment on the litigation. However, Florida voters will decide on adult-use legalization in November 2026, and the outcome of the federal litigation could influence the campaign. A return to Schedule I might energize prohibition advocates, while affirmation of Schedule III could support legalization arguments.

Texas

Texas maintains cannabis prohibition except for a limited low-THC medical program. The state didn't join the Nebraska-led coalition but filed an amicus brief supporting the challenge. Texas argued that Schedule III rescheduling undermines its prohibition laws by creating a perception that cannabis is federally approved. However, legal experts note that federal scheduling doesn't preempt stricter state laws, and Texas retains full authority to maintain prohibition regardless of federal classification.

Nebraska and Kansas

Nebraska and Kansas, the lead plaintiffs in the state coalition challenge, maintain full prohibition and have resisted medical legalization despite ballot initiatives and legislative proposals. Both states border Colorado, creating enforcement challenges as residents travel across state lines to purchase cannabis. The states argue that Schedule III rescheduling exacerbates these challenges by legitimizing cannabis and making prohibition harder to enforce. However, data shows that cannabis arrests in Nebraska and Kansas declined by only 3% following the rescheduling, suggesting limited practical impact.

Ohio

Ohio legalized adult use through a ballot initiative in November 2023, with sales launching in August 2024. The state's program is structured around competitive licensing, with 350 dispensary licenses awarded through a lottery system. Schedule III rescheduling occurred during Ohio's implementation phase, and regulators designed tax structures assuming 280E elimination. A reversal would require Ohio to restructure its tax system and could reduce projected revenue by $120 million annually.

Further Reading

• DEA Final Rule, "Schedules of Controlled Substances: Rescheduling of Marijuana," 89 Fed. Reg. 44,674 (May 16, 2024) — https://www.federalregister.gov/documents/2024/05/21/2024-10633/schedules-of-controlled-substances-rescheduling-of-marijuana
• HHS Recommendation Letter to DEA (August 30, 2023) — https://www.hhs.gov/sites/default/files/cannabis-scheduling-recommendation.pdf
• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.deadiversion.usdoj.gov/21cfr/21usc/index.html
• Cannabis Freedom Alliance Petition for Review, D.C. Circuit Case No. 24-1286 (filed May 18, 2024)
• Nebraska v. DEA Complaint, N.D. Tex. Case No. 5:24-cv-00156 (filed June 3, 2024)
• Loper Bright Enterprises v. Raimondo, 144 S. Ct. 2244 (2024) — https://www.supremecourt.gov/opinions/23pdf/22-451_7m58.pdf
• Congressional Research Service, "Marijuana: Medical and Retail—Selected Legal Issues" (updated March 2026) — https://crsreports.congress.gov
• National Conference of State Legislatures, "State Medical Cannabis Laws" (updated monthly) — https://www.ncsl.org/health/state-medical-cannabis-laws